MedTrace Logo

Genetic Polymorphism and Retinopathy of Prematurity: Correlation of Clinical Presentations and Severity

NCT05132257 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 500

Last updated 2023-05-06

No results posted yet for this study

Summary

Study Aim and Goals

1. Evaluate the correlation between genetic polymorphism and ROP development
2. To study the possibility if there are any specific genetic polymorphisms that lead to poor outcome or recurrence of ROP after treatment.

Conditions

  • Retinopathy of Prematurity
  • Genetic Polymorphism

Interventions

PROCEDURE

Severe ROP

The treatment for ROP was either primary intravitreal injection (IVI) of anti-vascular endothelial growth factor (anti-VEGF) or laser photocoagulation or vitrectomy, and the indication for treatment was type 1 ROP, as defined by the ETROP Study.

Sponsors & Collaborators

  • Chang Gung Memorial Hospital

    lead OTHER

Principal Investigators

  • Wu WeiChi, M.D., PhD. · Chang Gung Memorial Hospital

Eligibility

Min Age
3 Years
Max Age
12 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-04-12
Primary Completion
2024-03-31
Completion
2024-03-31

Countries

  • Taiwan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05132257 on ClinicalTrials.gov